Search | Haematologica

P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA (300 Online Views)

R. Cassano Cassano^1|2, T. Martins³, D. Coffey⁴, G. Buda⁵, S. Galimberti⁵, L.M.A. Melillo², R. Donnelly¹, M. Kwok¹, D. Green¹, R. Banerjee¹, K. Cicero¹, T. Gooley¹, R. Silbermann⁴, P. Becker⁶, A.J. Cowan¹, D. Dima¹

¹ Fred Hutchinson Cancer Center, Seattle, USA

² Policlinico Riuniti Foggia, Hematology Division, Italy

³ University of Washington, Seattle, USA

⁴ University of Miami Hospital and Clinics-UHealth Tower, USA

⁵ University of Pisa, Italy

⁶ OHSU Hospital, Portland, USA

Relapsed Multiple Myeloma CART Drug Sensitivity

P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS (244 Online Views)

E. Searle^1|2, A. Lesokhin³, R. Niesvizky⁴, B. Arnulf⁵, S. Larson⁶, C.. Strouse⁷, C. Fernandez De Larrea⁸, D. Vesole⁹, Y. Nagai¹⁰, S.T. Sullivan¹¹, E. Leip¹¹, N. Bahlis¹²

¹ The Christie NHS Foundation Trust, Manchester, UK

² University of Manchester, UK

³ Memorial Sloan Kettering Cancer Center, New York, USA

⁴ Weill Cornell Medicine/New York Presbyterian Hospital, USA

⁵ Hôpital Saint-Louis, APHP, Université Paris, France

⁶ UCLA Medical Center, Santa Monica, USA

⁷ Carver College of Medicine,Iowa City, USA

⁸ Hospital Clínic, Barcelona, Spain

⁹ John Theurer Cancer Center, Hackensack, USA

¹⁰ Kobe City Medical Center General Hospital, Japan

¹¹ Pfizer Inc, Cambridge, USA

¹² Arnie Charbonneau Cancer Institute, Calgary, Canada

RRMM BCMA MagnetisMM-3

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (198 Online Views)

A. Perrot¹, M. Kortüm², R. Popat³, K. Uttervall⁴, M.V. Mateos⁵, K. Weisel⁶, K. Van Nimwegen⁷, J. Diels⁷, F. Ong⁷, R. Morano⁷, E. Rubio-Azpeitia⁷, P. Moreau⁸

¹ Universite de Toulouse, France

² University Hospital of Würzburg, Germany

³ University College London Hospitals NHS Foundation Trust, UK

⁴ Karolinska University Hospital, Stockholm, Sweden

⁵ Hospital Universitario de Salamanca, Spain

⁶ University Medical Center Hamburg-Eppendorf, Hamburg, Germany

⁷ Johnson & Johnson

⁸ University Hospital Hôtel-Dieu, Nantes, France

Multiple Myeloma RRMM Teclistamab

P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA (259 Online Views)

D. Dytfeld¹, L.J. Costa², A. Oriol³, S. Manier^4|5, P.M. Voorhees⁶, Y. Lin⁷, M. Htut⁸, W. Roeloffzen⁹, P. J. Ho^10|11, U. Shah^12|13, M. Zhao¹⁴, Q. Li¹⁵, A. Balogh¹⁵, K. Li¹⁵, A. Slaughter¹⁵, N. Benachour¹⁵, C. Lonardi¹⁵, A. Ghosh¹⁵, H. Sun¹⁵, N. Lendvai¹⁵, T. Lengil¹⁵, N. Patel¹⁶, M. Koneru¹⁶, E. Florendo¹⁶, O. C. Filho¹⁶, V. Mahajan¹⁶, P. Rodríguez-Otero¹⁷, C. Strouse¹⁸, A.K. Stewart^19|20, S. Sidana²¹

¹ Poznan University of Medical Sciences, Poznań, Poland

² University of Alabama at Birmingham, USA

³ Hospital Germans Trias i Pujol, Barcelona, Spain

⁴ University of Lille, France

⁵ Centre Hospitalier Universitaire Lille, France

⁶ Wake Forest University, Charlotte, USA

⁷ Mayo Clinic, Rochester, USA

⁸ City of Hope Comprehensive Cancer Center, Duarte, USA

⁹ University Medical Center Groningen, The Netherlands

¹⁰ Royal Prince Alfred Hospital, Sydney, Australia

¹¹ The University of Sydney, Australia

¹² Memorial Sloan Kettering Cancer Center, New York, USA

¹³ Weill Cornell Medical College, New York, USA

¹⁴ IQVIA, Shangai, China

¹⁵ Johnson & Johnson

¹⁶ Legend Biotech USA Inc, Somerset, USA

¹⁷ Universidad de Navarra, Pamplona, Spain

¹⁸ University of Iowa, Iowa City, USA

¹⁹ University Health Network, Toronto, Canada

²⁰ The Princess Margaret Cancer Centre, Toronto, Canada

²¹ Stanford University, USA

CARTITUDE-4 Multiple Myeloma Progression free

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (265 Online Views)

R. Popat¹, N.W.C.J. Van De Donk^2|3, B. Faiman⁴, J. Yuda⁵, K. Kim⁶, A. Costa⁷, A. Laheij^2|3, R.L. Doty⁸, J. Omel⁹, B. Lipe¹⁰, L. Sanchez¹¹, A. Chari¹², A. Lin¹³, H. Sroussi¹⁴, M. Fernandez¹⁵, K.S. Gray¹⁵, G. Aguilar¹⁵, K. Bolyard¹⁵, J. Schultz¹⁵, K. Qi¹⁵, D. Cortes-Selva¹⁵, J. Zhang¹⁵, C. Heuck¹⁵, K. Hawks¹⁵, K. Tian¹⁵, M. França¹⁵, L. Rasche¹⁶

¹ University College London Hospitals NHS Foundation Trust, UK

² Amsterdam University Medical Center, The Netherlands

³ Vrije Universiteit Amsterdam, The Netherlands

⁴ Cleveland Clinic, USA

⁵ National Cancer Center Hospital East, Kashiwa, Japan

⁶ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁷ D’or Institute for Research and Education, São Paulo, Brazil

⁸ University of Pennsylvania Smell and Taste Center, Philadelphia, USA

⁹ The Central Nebraska Myeloma Support Group, Grand Island, USA

¹⁰ University of Rochester Medical Center, USA

¹¹ Icahn School of Medicine at Mount Sinai, New York, USA

¹² University of California, San Francisco, USA

¹³ University of Pennsylvania, Philadelphia, USA

¹⁴ Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA

¹⁵ Johnson & Johnson

¹⁶ University Hospital of Würzburg, Germany

TALISMAN study Multiple Myeloma RRMM

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (198 Online Views)

I. Vigliotta¹, A. Varacalli¹, M. Talarico^1|2, M. Puppi^1|2, S. Armuzzi², B. Taurisano², I. Pistis¹, V. Solli², V. M. Vuong², E. Borsi¹, A. Vitale¹, G. Mazzocchetti^3|4, A. Croce², M. Martello¹, A. Poletti², M. Cavo², E. Manzato^1|2, E. Zamagni^1|2, C. Terragna¹

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

² Department of Medical and Surgical Sciences - University of Bologna, Italy

³ FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy

⁴ Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy

RRMM CAR-T Circulating plasma cells

P18 | MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA (263 Online Views)

I. Vigliotta¹, A. Varacalli¹, M. Talarico^1|2, V. Solli², B. Taurisano², S. Armuzzi², I. Pistis¹, V.M. Vuong², A. Vitale¹, G. Mazzocchetti^3|4, E. Borsi¹, A. Croce², M. Martello¹, A. Poletti², C. Nanni⁵, K. Mancuso^1|2, M. Puppi^1|2, M. Cavo², E. Zamagni^1|2, C. Terragna¹

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy

² Department of Medical and Surgical Sciences - University of Bologna, Italy

³ FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy

⁴ Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy

⁵ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, Italy

Circulating Plasma Cells Multiple Myeloma NDMM

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (237 Online Views)

C. Mo¹, C. Gasparetto², C. Costa², A.J. Cowan³, T. Mark⁴, Y. Chai⁴, T. Kashyap⁴, J. Katz⁵, M. Amatangelo⁵, P.G. Richardson¹

¹ Dana-Farber Cancer Institute, Boston, USA

² Duke Cancer Institute, Durham, USA

³ University of Washington, Seattle, USA

⁴ Karyopharm Therapeutics, Newton, USA

⁵ Bristol Myers Squibb, Princeton, USA

Multiple Myeloma RRMM STOMP trial

P22 | WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (247 Online Views)

A. Belotti¹, S. Terlizzi², S. Martorana², R. Ribolla¹, C. Crippa¹, S. Ferrari¹, N. Bianchetti¹, C. Bottelli¹, C. Cattaneo¹, M. Chiarini³, V. Giustini³, A. Roccaro⁴, A. Tucci¹

¹ Department of Hematology, ASST Spedali Civili di Brescia, Italy

² University of Brescia, Italy

³ Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Italy

⁴ Clinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Italy

CASSIOPEIA trial Dara-VTd Transplant-eligible

P33 | ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS (542 Online Views)

S. Bal¹, M. Htut², J. Berdeja³, L. Anderson⁴, A. Rossi⁵, T. Gregory⁶, L. Costa¹, H. Hu⁷, Z. Guo⁷, J. Chen⁷, K. Jordahl⁷, N. Sarkis⁷, S. Ziyad⁷, W.M. Kao⁷, A. Kaeding⁷, M. Burgess⁷, O. Nadeem⁸

¹ University of Alabama at Birmingham, USA

² City of Hope Comprehensive Cancer Center, Duarte, USA

³ Greco-Hainsworth Tennessee Oncology Center for Research, Nashville, USA

⁴ Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA

⁵ Icahn School of Medicine at Mount Sinai, New York, USA

⁶ Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, USA

⁷ Bristol Myers Squibb, Princeton, USA

⁸ Dana-Farber Cancer Institute, Boston, USA

RRMM CAR-T cells BCMA

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (244 Online Views)

R. Popat¹, K. Uttervall², K.M. Kortüm³, H. Magen⁴, M. Hansson⁵, T. Shragai⁶, E. Terpos⁷, C. T. Hansen⁸, S. Manier^9|10, H. Gregersen¹¹, Ø.M. Ottestad¹², C. Touzeau¹³, E. Hatjiharissi^14|15, S.L. Farmer¹⁶, E. Katodritou¹⁷, E. Spanoudakis¹⁸, M.Ø. Vase¹⁹, C. Liberatore^20|21, M. Papathanasiou²², M.K. Angelopoulou^7|23, E. Clavero²⁴, R. Kittus²⁵, P. Smirnov²⁵, P. Hu²⁵, D. Santra²⁶, C. Albrecht²⁵, E. Rubio-Azpeitia²⁵, A. Perrot²⁷

¹ University College London Hospitals NHS Foundation Trust, UK

² Karolinska University Hospital, Stockholm, Sweden

³ University Hospital of Würzburg, Germany

⁴ Tel-Aviv University, Israel

⁵ Sahlgrenska University Hospital, Gothenburg, Sweden

⁶ Tel-Aviv Sourasky Medical Center, Israel

⁷ National and Kapodistrian University of Athens, Greece

⁸ Odense University Hospital, Denmark

⁹ University of Lille, France

¹⁰ Centre Hospitalier Universitaire Lille, France

¹¹ Aalborg University Hospital, Denmark

¹² Akershus University Hospital, Lørenskog, Norway

¹³ University Hospital Hôtel-Dieu, Nantes, France

¹⁴ AHEPA University Hospital, Thessaloniki, Greece

¹⁵ Aristotle University of Thessaloniki, Greece

¹⁶ Vejle Hospital, Denmark

¹⁷ Theagenio Cancer Hospital, Thessaloniki, Greece

¹⁸ Democritus University of Thrace, Alexandroupolis, Greece

¹⁹ Aarhus University Hospital, Denmark

²⁰ Santo Spirito Hospital, Pescara, Italy

²¹ "G d'Annunzio" University, Chieti, Italy

²² G Papanicolaou Hospital, Thessaloniki, Greece

²³ Laiko General Hospital, Athens, Greece

²⁴ Hospital Universitario Virgen De Las Nieves, Granada, Spain

²⁵ Johnson and Johnson

²⁶ Parexel International on behalf of Johnson & Johnson, Sheffield, UK

²⁷ Université de Toulouse, France

REALiTEC-2 Trial RRMM Teclistamab

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (291 Online Views)

M.V. Mateos¹, P. Rodríguez-Otero², S.Z. Usmani³, S. Kumar⁴, J.C. Ye⁵, S. Atrash⁶, H. Magen⁷, H. Quach⁸, M.P. Chu⁹, S. Trudel¹⁰, J. Richter¹¹, H. Chuah¹², M. Gatt¹³, E. Medvedova¹⁴, S. Raza¹⁵, D.H. Yoon¹⁶, T. Ishida¹⁷, J.V. Matous¹⁸, L. Rosiñol¹⁹, K. Onodera²⁰, C. Maffucci²¹, E. Scott²¹, C. Heuck²¹, J. Zhang²¹, T. Henninger²¹, L. O’Rourke²¹, P. Thakkar²¹, M. Festa²¹, L. Huang²¹, J. Zhou²¹, M. Takamoto²¹, L. Pei²¹, J. Lu²¹, N. Au²¹, M. Krevvata²¹, Y.C. Cohen⁷

¹ University Hospital of Salamanca, Spain

² Cancer Center Clínica Universidad de Navarra, Pamplona, Spain

³ Memorial Sloan Kettering Cancer Center, New York, USA

⁴ Mayo Clinic Rochester, USA

⁵ University of Texas, Houston, USA

⁶ Levine Cancer Institute-Atrium Health, Charlotte, USA

⁷ Tel Aviv University, Israel

⁸ University of Melbourne, Australia

⁹ Alberta Health Services, Edmonton, Canada

¹⁰ Princess Margaret Cancer Centre, Toronto, Canada

¹¹ Mount Sinai Medical Center, New York, USA

¹² Royal Perth Hospital, Australia

¹³ Hebrew University of Jerusalem, Israel

¹⁴ Oregon Health and Science University, Portland, USA

¹⁵ Cleveland Clinic, USA

¹⁶ University of Ulsan College of Medicine, Seoul, Korea

¹⁷ Japanese Red Cross Medical Center, Tokyo, Japan

¹⁸ Colorado Blood Cancer Institute, Denver, USA

¹⁹ Hospital Clínic de Barcelona, Spain

²⁰ Tohoku University Hospital, Sendai, Japan

²¹ Johnson & Johnson

Multiple Myeloma RedirecTT-1 trial RRMM

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (243 Online Views)

E. Searle¹, V. Campbell², C. Pawlyn³, D. Vogl⁴, S. Holstein⁵, S. Gooding⁶, M. Jenner⁷, T. Creasey⁸, A. Chaidos⁹, P. Rodríguez-Otero¹⁰, F. Al-Kaisi¹¹, A. Brearton¹², S. Moore⁶, J. O’Nions¹³, T. Somervaille¹, T. Knurowski¹⁴, K. Clegg¹⁴, S. Paul¹⁴, K. Frese¹⁴, N. Joseph¹⁵

¹ The Christie NHS Foundation Trust, Manchester, UK

² Western General Hospital, Edinburgh, UK

³ The Royal Marsden NHS Foundation Trust, London, UK

⁴ Hospital of the University of Pennsylvania, Philadelphia, USA

⁵ University of Nebraska Medical Center, Omaha, USA

⁶ Oxford University Hospitals NHS Foundation Trust, Oxford, UK

⁷ University Hospital Southampton NHS Foundation Trust, UK

⁸ Northern Centre for Cancer Care, Newcastle upon Tyne, UK

⁹ Imperial College Healthcare NHS Trust, London, UK

¹⁰ Clínica Universidad de Navarra, Pamplona, Spain

¹¹ Royal Derby Hospital, UK

¹² The Clatterbridge Cancer Centre, Liverpool, UK

¹³ University College London Hospital, UK

¹⁴ CellCentric Ltd, Cambridge, UK

¹⁵ Emory Winship Cancer Institute, Atlanta, USA

Multiple Myeloma Inobrodib RRMM

P38 | SAFETY AND EFFICACY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM PHASE 1b OF RedirecTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS (232 Online Views)

E.M. Ocio^1|2, M-V. Mateos³, H. Magen⁴, M. Gatt⁵, M. Sebag⁶, K. Kim⁷, C-K. Min⁸, S-S. Yoon⁹, M.P. Chu¹⁰, P. Rodríguez-Otero¹¹, I. Avivi⁴, N.A. Quijano Cardé¹², M. Krevvata¹², T. Henninger¹², P. Thakkar¹², M. Festa¹², L. Huang¹², J.X. Zhou¹², M. Takamoto¹², L. Pei¹², J. Lu¹², C. Maffucci¹², E. Scott¹², A. Oriol¹³, D. Morillo¹⁴, Y.C. Cohen⁴

¹ Hospital Universitario Marqués de Valdecilla, Santander, Spain

² Universidad de Cantabria, Santander, Spain

³ University Hospital of Salamanca, Spain

⁴ Tel Aviv University, Israel

⁵ Hebrew University of Jerusalem, Israel

⁶ McGill University, Montreal, Canada

⁷ Sungkyunkwan University School of Medicine, Seoul, Korea

⁸ The Catholic University of Korea, Seoul, Korea

⁹ Seoul National University College of Medicine, Korea

¹⁰ Alberta Health Services, Edmonton, Canada

¹¹ Cancer Center Clínica Universidad de Navarra, Pamplona, Spain

¹² Johnson & Johnson

¹³ Hospital Germans Trias i Pujol, Badalona, Spain

¹⁴ University Hospital Fundación Jiménez Díaz, Madrid, Spain

RRMM RedirecTT-1 Follow-up

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (299 Online Views)

R. Popat¹, K.M. Kortüm², H. Magen³, V. Mykytiv⁴, C. Liberatore⁵, E. Zamagni⁶, M.C. Da Vià⁷, E. Antonioli⁸, M. Hansson⁹, D. Santra¹⁰, D. Greer¹⁰, K. Subrt¹¹, P. Hu¹¹, E. Aeby¹¹, N. Francella¹¹, N.M. Suñe¹¹, A. Perrot¹², K. Uttervall¹³

¹ University College London Hospitals NHS Foundation Trust, UK

² University Hospital of Würzburg, Germany

³ Tel Aviv University, Israel

⁴ Cork University Hospital, Ireland

⁵ Ospedale Santo Spirito, Pescara, Italy

⁶ University of Bologna, Italy

⁷ IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

⁸ Careggi Hospital and University of Florence, Italy

⁹ Sahlgrenska University Hospital, Gothenburg, Sweden

¹⁰ Parexel International

¹¹ Johnson & Johnson

¹² Université de Toulouse, France

¹³ Karolinska University Hospital, Stockholm, Sweden

Multiple Myeloma REALiTAL Trial RRMM

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (281 Online Views)

E. Zamagni¹, B. Dhakal², S. Iida³, M.H. Sidiqi^4|5, S.S. Yoon⁶, N. Callander⁷, C. Touzeau^8|9|10|11, Q. Li¹², A. Balogh¹², A. Slaughter¹², N. Benachour¹², C. Lonardi¹², A. Ghosh¹², M. Vogel¹², N. Lendvai¹², T. Lengil¹², M. Koneru¹³, N. Patel¹³, O. Costa Filho¹³, V. Mahajan¹³, J. Martínez-López¹⁴, K. Yong¹⁵, K. Weisel¹⁶, X. Leleu¹⁷

¹ University of Bologna, Italy

² Medical College of Wisconsin, Milwaukee, USA

³ Nagoya City University, Japan

⁴ Fiona Stanley Hospital, Perth, Australia

⁵ Curtin University, Perth, Australia

⁶ Seoul National University, Korea

⁷ University of Wisconsin, Madison, USA

⁸ Centre Hospitalier Universitaire Hotel Dieu, Nantes, France

⁹ Université d’Angers, Nantes, France

¹⁰ Université de Nantes, France

¹¹ French Ministry of Health, Nantes, France

¹² Johnson & Johnson

¹³ Legend Biotech USA Inc, Somerset, USA

¹⁴ Complutense University, Madrid, Spain

¹⁵ University College London, UK

¹⁶ University Medical Center Hamburg-Eppendorf, Hamburg, Germany

¹⁷ CHU Poitiers, France

Multiple Myeloma CARTITUDE-4

P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP (252 Online Views)

E. Terpos¹, E. Kastritis¹, S. Delimpasi², K. Papathanasiou³, V. Labropoulou⁴, N. Kanellias¹, I.N. Stathopoulos¹, M. Migkou¹, E. Solia¹, F. Theodorakakou¹, E.E. Papaiakovou¹, M. Kotsopoulou⁵, E. Katodritou⁶, M. Gavriatopoulou¹, M.A. Dimopoulos^1|7

¹ National and Kapodistrian University of Athens, Greece

² Evangelismos Hospital, Athens, Greece

³ University of Ioannina, Greece

⁴ University of Patras, Medical School, Greece

⁵ Metaxa Cancer Hospital,Piraeus, Greece

⁶ Theagenio Cancer Hospital, Thessaloniki, Greece

⁷ Korea University, Seoul, South Korea

Greek Myeloma Study Group NDMM Isa-VRd

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (239 Online Views)

N.W.C.J. Van De Donk¹, R. Wester², I. Nijhof³, C. Albrecht⁴, R. Morano⁵, C. Entrala⁶, K. Van Nimwegen^1|2|3|4|5|6

¹ Amsterdam University Medical Center, The Netherlands

² Erasmus Medical Center, Rotterdam, The Netherlands

³ St. Antonius Ziekenhuis, Nieuwegein, The Netherlands

⁴ Johnson & Johnson, Paris, France

⁵ Johnson & Johnson, Madrid, Spain

⁶ Johnson & Johnson, Breda, The Netherlands

Multiple Myeloma RRMM Treatment Management

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (237 Online Views)

R. Popat¹, S. Harrison², C. H. Riley³, H.S. Mian⁴, A. Spencer⁵, N. Lavi⁶, L. Paris⁷, T. Jelínek⁸, M. Szarejko⁹, S. Grosicki¹⁰, K. Kim¹¹, I. Sandhu¹², S. Chebon¹³, T. Tyagi¹⁴, P. Sewpaul¹⁵, L. Richardson¹⁵, K. Trunzer¹³, A. Mishra¹⁴, S. Trudel¹⁶

¹ University College London Hospitals NHS Foundation Trust, UK

² Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University and The Royal Melbourne Hospital, Australia

³ Rigshospitalet, Copenhagen, Denmark

⁴ McMaster University, Hamilton, Canada

⁵ Alfred Health-Monash University, Melbourne, Australia

⁶ Rambam Health Care Campus, Haifa, Israel

⁷ ASST Papa Giovanni XXIII, Bergamo, Italy

⁸ Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Czech Republic

⁹ Medical University of Gdansk, Poland

¹⁰ Medical University of Silesia, Katowice, Poland

¹¹ Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea

¹² Cross Cancer Institute, University of Alberta, Edmonton, Canada

¹³ F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹⁴ Genentech, Inc, South San Francisco, USA

¹⁵ Roche Products Ltd, Welwyn, UK

¹⁶ Princess Margaret Cancer Centre and University of Toronto, Canada

CAMMA 1 study BCMA Multiple Myeloma

P57 | MELFLUFEN IS EFFECTIVE AND SAFE IN MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT (205 Online Views)

C. Bellofiore¹, V. Del Fabro², C. Finocchiaro³, F. Elia^1|3, D. Leotta³, B. Garibaldi¹, A. Petronaci³, F. Di Raimondo^1|3, A. Romano^1|3, C. Conticello¹

¹ Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy

² Faculty of Medicine and Surgery, “Kore” University of Enna, Italy

³ Postgraduate School of Hematology, University of Catania, Italy

RRMM Renal impairment Melflufen

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (214 Online Views)

N. Sgherza¹, E. Antonioli², E. Zamagni^3|4, C. Conticello⁵, F. Fazio⁶, S. Palmieri⁷, A. Cagnetta⁸, G. Palumbo⁹, A.G. Solimando¹⁰, R. Della Pepa¹¹, C. Germano¹², G. Palazzo¹³, C. De Risi¹⁴, A. Quinto¹⁵, G. Buda¹⁶, M. Gentile^17|18, O. Annibali¹⁹, D. De Novellis²⁰, P. Curci¹, O. Battisti¹, L. Pavan^21|22, M. Capriata⁶, G. Di Carlo¹³, G. Proietti⁶, V. Del Fabro²³, A.P. Falcone²⁴, R. Spadano²⁵, D. Derudas²⁶, G. Mele²⁷, G. Barilà²⁸, M.T. Petrucci⁶, F. Di Raimondo^5|29, F. Albano^1|30, P. Musto^1|30

¹ Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy

² Hematology Unit, Careggi University Hospital, Firenze, Italy

³ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli", Italy

⁴ Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy

⁵ Division of Hematology and Stem Cell Transplantation, Policlinico“G. Rodolico-San Marco”, Catania, Italy

⁶ Department of Translational and Precision Medicine Hematology, Sapienza University, Roma, Italy

⁷ Hematology Unit, Ospedale Cardarelli, Napoli, Italy

⁸ Hematology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

⁹ Hematology Unit, AOU Policlinico Riuniti di Foggia, Italy

¹⁰ G. Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Italy

¹¹ Department of Clinical Medicine and Surgery, University Federico II, Napoli,Italy

¹² Hematology Unit,“Mons. Dimiccoli” Hospital, Barletta, Italy

¹³ Hematology Unit, “G. Moscati” Hospital, Taranto, Italy

¹⁴ Haematology and Transplant Unit, “V. Fazzi” Hospital, Lecce, Italy

¹⁵ Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”, Bari, Italy

¹⁶ Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy

¹⁷ Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Italy

¹⁸ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Italy

¹⁹ Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Biomedico di Roma, Italy

²⁰ Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy

²¹ Department of Medicine

²² (DIMED), Hematology section, Padua University School of Medicine, Italy

²³ Faculty of Medicine and Surgery “Kore”, University of Enna, Italy

²⁴ Department of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy

²⁵ Hematology Unit, Santo Spirito Hospital, Pescara, Italy

²⁶ Department of Hematology, Businco Hospital, Cagliari, Italy

²⁷ Hematology Unit,“A. Perrino” Hospital, Brindisi, Italy

²⁸ Hematology Unit, Ospedale San Bortolo, Vicenza, Italy

²⁹ Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, Italy

³⁰ Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy

Multiple Myeloma ODISSEY study Clinical Features

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (202 Online Views)

M.C. Vekemans¹, O. Rizzo², N. Meuleman²

¹ Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium

² Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium

AL Amyloidosis Multiple Myeloma anti-BCMA

P60 | TRIAL IN PROGRESS, MoMMent-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (267 Online Views)

K. Weisel¹, E. Kastritis², E. Gonzalez-Garcia³, S. Gentili⁴, C. Renner⁵, P. Ferraz⁶, N. Francella⁷, S. Sitar⁷, J. Buyze⁷, N. Healy⁷, N.M. Suñé⁷, P. Moreau⁸, M.V. Mateos⁹

¹ University Medical Center Hamburg-Eppendorf, Hamburg, Germany

² National and Kapodistrian University of Athens, Greece

³ University Hospital Cabueñes, Gijón, Spain

⁴ UOSD Ematologia Civitanova Marche AST Macerata, Civitanova Marche, Italy

⁵ Klinik Hirslanden, Zurich, Switzerland

⁶ Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal

⁷ Johnson & Johnson Innovative Medicine

⁸ Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France

⁹ University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain

LocoMMotion Trial MoMMent Trial Real-world Practice

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (253 Online Views)

E. Lebel¹, A. Abdulgawad², S. Bramanti³, G. Garate⁴, P.J. Ho⁵, M. Keränen⁶, Y. Cohen⁷, M. Vase⁸, A. Khot⁹, I. Kristensen¹⁰, R. Leblanc¹¹, C. Lee¹², W. Legiec¹³, H. Magen¹⁴, M.V. Mateos¹⁵, D. Oh¹⁶, L. Pour¹⁷, N. Schutz¹⁸, A. Spyridonidis¹⁹, K. Weisel²⁰, J. Zaucha²¹, S. Larson²², A. Varshavsky-Yanovsky²³, K. Grazioli²⁴, D. Basudhar²⁴, H. Hu²⁴, Y. Meng²⁴, L. Eldjerou²⁴, S. Bal²⁵, S. Harrison⁹, R. Popat²⁶, M. Raab²⁷, P. Rodriguez-Otero²⁸

¹ Hadassah Medical Center, Jerusalem, Israel

² Christie NHS Foundation Trust, Manchester, UK

³ IRCCS Istituto Clinico Humanitas, Rozzano, Italy

⁴ Hospital Aleman, Buenos Aires, Argentina

⁵ Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia

⁶ Helsinki University Hospital, Finland

⁷ Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel

⁸ Aarhus Universitetshospital, Midtjylland, Denmark

⁹ Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia

¹⁰ Odense Universitetshospital, Denmark

¹¹ Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada

¹² Royal Adelaide Hospital, Australia

¹³ St. John of Dukla Oncology Center of Lublin Land,Poland

¹⁴ Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel

¹⁵ Hospital Universitario de Salamanca, Spain

¹⁶ Monash Health and Monash University, Clayton, Victoria, Australia

¹⁷ Masaryk University and University Hospital Brno, Czech Republic

¹⁸ Hospital Italiano de Buenos Aires, Argentina

¹⁹ University Hospital of Patras, Greece

²⁰ University Medical Center Hamburg-Eppendorf, Germany

²¹ Medical University of Gdańsk and University Clinical Center, Poland

²² UCLA Medical Center, Los Angeles, USA

²³ Fox Chase Cancer Center Temple Health, Philadelphia, USA

²⁴ Bristol Myers Squibb, Princeton, USA

²⁵ University of Alabama at Birmingham, USA

²⁶ University College London Hospital, UK

²⁷ Universitaetsklinikum Heidelberg, Germany

²⁸ Clinica Universidad de Navarra, Pamplona, Spain

QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (200 Online Views)

D. Stoumbos¹, A. Antoniou¹, K. Lampropoulos¹, S. Chrysoglou¹, C. Prifti¹, M. Panagiotouni¹, M. Dadakaridou¹, S. Giourgouli², K. Stefanidis³, M. Kotsopoulou¹

¹ Metaxa Cancer Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Athens, Greece

² Metaxa Cancer Hospital, Nuclear Medicine Department, Athens, Greece

³ Metaxa Cancer Hospital, Department of Radiology, Athens, Greece

Multiple Myeloma Elderly Bispecific antibodies

Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026

Advanced filters

Keyword matches

P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA (300 Online Views)

Title matches

P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS (244 Online Views)

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (198 Online Views)

P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA (259 Online Views)

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (265 Online Views)

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (198 Online Views)

P18 | MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA (263 Online Views)

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (237 Online Views)

P22 | WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (247 Online Views)

P33 | ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS (542 Online Views)

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (244 Online Views)

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (291 Online Views)

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (243 Online Views)

P38 | SAFETY AND EFFICACY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM PHASE 1b OF RedirecTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS (232 Online Views)

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (299 Online Views)

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (281 Online Views)

P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP (252 Online Views)

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (239 Online Views)

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (237 Online Views)

P57 | MELFLUFEN IS EFFECTIVE AND SAFE IN MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT (205 Online Views)

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (214 Online Views)

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (202 Online Views)

P60 | TRIAL IN PROGRESS, MoMMent-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (267 Online Views)

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (253 Online Views)

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (200 Online Views)

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More